1	Sex influences the effects of APOE genotype and Alzheimer's diagnosis on neuropathology
2	and memory
3	Paula Duarte-Guterman <sup>1#</sup> , Arianne Y. Albert <sup>2</sup> , Cindy K. Barha <sup>3</sup> , Liisa A.M. Galea <sup>1</sup> , on behalf of
4	the Alzheimer's Disease Neuroimaging Initiative <sup><math>\delta</math></sup>
5	
6	<sup>1</sup> Djavad Mowafaghian Centre for Brain Health and Department of Psychology, University of
7	British Columbia, Vancouver, BC, Canada
8	<sup>2.</sup> Women's Health Research Institute of British Columbia, Vancouver, BC, Canada
9	<sup>3.</sup> Djavad Mowafaghian Centre for Brain Health and Department of Physical Therapy, University
10	of British Columbia, Vancouver, BC, Canada
11 12 13 14 15 16 17 18 19 20	Address all correspondence and requests for reprints to: L. A. M. Galea, PhD Djavad Mowafaghian Centre for Brain Health 2215 Wesbrook Mall Vancouver, British Columbia V6T 1Z3, Canada E-mail: <u>liisa.galea@ubc.ca</u>
20 21 22 23 24 25 26 27 28 29 30 31 32 22	<sup>#</sup> Present Address: Department of Psychology, Brock University, St. Catharines, ON, Canada <sup>δ</sup> Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp- content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf
33	<b>Keywords:</b> mild cognitive impairment; tau, amyloid beta; hippocampus; executive function;
34	gender.

## 35 Abstract

Alzheimer's disease (AD) is characterised by severe cognitive decline and pathological 36 37 changes in the brain (brain atrophy, hyperphosphorylation of tau, and deposition of toxic amyloid-beta protein). Females have greater neuropathology (AD biomarkers and brain atrophy 38 rates) and cognitive decline than males, however these effects can depend on diagnosis (amnestic 39 40 mild cognitive impairment (aMCI) or AD) and APOE genotype (presence of ɛ4 alleles). Using the ADNI database (N=630 females, N=830 males), we analysed the effect of sex, APOE 41 42 genotype (non-carriers or carriers of APOEɛ4 alleles), and diagnosis (cognitively normal (CN), 43 early aMCI (EMCI), late aMCI (LMCI), probable AD) on cognition (memory and executive function), hippocampal volume, and AD biomarkers (CSF levels of amyloid beta, tau and ptau). 44 Regardless of APOE genotype, memory scores were higher in CN, EMCI, and LMCI females 45 compared to males but this sex difference was absent in probable AD, which may suggest a 46 47 delay in the onset of cognitive decline or diagnosis and/or a faster trajectory of cognitive decline 48 in females. We found that, regardless of diagnosis, CSF tau-pathology was disproportionately elevated in female carriers of APOEɛ4 alleles compared to males. In contrast, male carriers of 49 APOEE4 alleles had reduced levels of CSF amyloid beta compared to females, irrespective of 50 51 diagnosis. We also detected sex differences in hippocampal volume but the direction was 52 dependent on the method of correction. Altogether results suggest that across diagnosis females 53 show greater memory decline compared to males and APOE genotype affects AD 54 neuropathology differently in males and females which may influence sex differences in 55 incidence and progression of aMCI and AD.

## 56 **1. Introduction**

57 Alzheimer's disease (AD) is characterized by severe cognitive decline and neuropathological markers such as brain atrophy, hyperphosphorylation of tau, and deposition of 58 toxic amyloid-beta (A $\beta$ ) protein in the brain (Alzheimer's Association, 2017). The hippocampus 59 60 is one of the first brain areas to show atrophy with AD (Jack et al., 2000; Kidron et al., 1997) and hippocampal atrophy correlates with cognitive decline (Petersen et al., 2000) and AD pathology 61 (neurofibrillary tangles; Jack et al., 2002). Possession of one or two APOEɛ4 alleles, the 62 strongest genetic risk factor for sporadic AD, and female sex are important non-modifiable risk 63 factors for AD (Riedel et al., 2016). Studies indicate that females with AD show greater signs of 64 neuropathology (tau levels), rates of brain atrophy, including in the hippocampus, and cognitive 65 66 decline than males, which may be exacerbated by APOE genotype (e.g., Ardekani et al., 2016; Buckley et al., 2018; Cavedo et al., 2018; Hohman et al., 2018). One allele of APOEɛ4 increases 67 68 the risk of AD in females relative to males between 65 and 75 years, indicating that the APOE 69 genotype affects males and females differently (Neu et al., 2017). Previous studies have examined the interaction of APOE genotype and sex on AD 70 71 biomarkers (tau and A $\beta$ ), hippocampal atrophy, and cognitive function, but findings are not consistent (Altmann et al., 2014; Buckley et al., 2018; Damoiseaux et al., 2012; Holland et al., 72 2013; Liu et al., 2019; Sampedro et al., 2015; Sohn et al., 2018; Wang et al., 2019), likely due to 73 the diagnosis groups included and whether studies use longitudinal or baseline comparisons. 74 Using the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, previous studies found 75 a stronger association between APOEE4 and CSF tau levels in females compared to males at 76 baseline in cognitively normal (CN; Damoiseaux et al., 2012; but see Sampedro et al., 2015) and 77 amnestic mild cognitive impairment (aMCI) individuals (Altmann et al., 2014; Liu et al., 2019) 78 79 but no studies to our knowledge have investigated the interactions between sex and APOE

genotype in individuals with AD. Females with APOE $\varepsilon$ 4 alleles have steeper hippocampal 80 volume reductions with age in CN individuals (Holland et al., 2013) and show greater cognitive 81 82 decline in aMCI individuals (Sohn et al., 2018; Wang et al., 2019) compared to males but these findings are not consistent (Buckley et al., 2018). Although there are several ADNI studies that 83 have examined sex by APOE genotype interactions on AD biomarkers, most of these studies 84 85 included only one diagnosis group, with either only CN (Buckley et al., 2018, 2019a) or aMCI groups (Liu et al., 2019; Sohn et al., 2018) or analysed the groups (CN, aMCI, AD) separately 86 87 (Sundermann et al., 2018). It is important to include all three diagnosis groups CN, aMCI and AD to understand how sex may interact with APOE genotype to influence AD biomarkers across 88 diagnosis. In order to improve diagnosis and treatment, it is important to understand why females 89 are at a higher lifetime risk and have a higher burden of the disease than males and whether this 90 is across diagnosis and APOE genotype for a number of AD biomarkers. 91

92 Sex differences in memory depend on memory domain, females perform better in 93 episodic memory tasks related to verbal memory, whereas males perform better in visuospatialrelated tasks (meta-analysis by Asperholm et al., 2019). Furthermore, there are sex differences in 94 some forms of executive function depending on the type of executive function being examined, 95 96 with a male advantage for working memory and a female advantage on response inhibition in cognitively healthy adults (Gaillard et al., 2020). In tasks that involve the integrity of the 97 98 hippocampus, males typically outperform females in both humans and rodents (Yagi and Galea, 99 2019). In addition, while sex differences in hippocampal volume have been detected, with 100 females having a smaller volume compared to males, this depends on whether the data are 101 corrected for individual differences in brain volume and the method of correction employed 102 (meta-analysis by Tan et al., 2016). Understanding basic sex differences in hippocampal function

and structure is important to determine how they can contribute to sex differences in
vulnerability and progression of neurodegenerative diseases in which the integrity of the
hippocampus is affected such as in AD.

106 The objective of this study was to examine sex differences in AD biomarkers (CSF A $\beta$ , 107 tau, and phosphorylated tau), volume of the hippocampus (using two correction factors), 108 memory, and executive function, and how these may be affected by APOE genotype (non-109 carriers or carriers of APOE $\epsilon$ 4 alleles) and diagnosis status (CN, aMCI, probable AD). We 110 hypothesized that females will be more affected by APOE genotype and diagnosis and this will 111 be reflected in greater AD pathology, smaller hippocampus volume, and lower cognitive scores 112 than males with probable AD and this is exacerbated in female carriers of APOE $\epsilon$ 4 alleles.

113

## 114 **2. Materials and methods**

#### 115 *2.1 ADNI database*

Data used in the preparation of this article were obtained from the Alzheimer's Disease 116 Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was launched in 117 118 2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial magnetic resonance imaging 119 (MRI), positron emission tomography (PET), other biological markers, and clinical and 120 121 neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (AD). For up-to-date information, see 122 www.adni-info.org. Data used in this article were downloaded on or before Jan 16, 2019. 123 Participants (between the ages of 55 and 90) were recruited across the United States and Canada 124 and agreed to complete a variety of imaging and clinical assessments at baseline and repeated at 125 126 specific intervals (Petersen et al., 2010). The study design and schedule is available online:

(http://adni.loni.usc.edu/study-design/). Inclusion and exclusion criteria are detailed online 127 (http://adni.loni.usc.edu/methods/documents/). Briefly, CN participants had normal memory 128 129 function (measured by education-adjusted scores on the Wechsler Memory Scale Logical Memory II) and a Clinical Dementia Rating (CDR) of 0. Amnestic late MCI (LMCI) participants 130 had objective memory loss (from Wechsler Memory Scale Logical Memory II scores), a CDR of 131 132 0.5, preserved daily activities, and absence of dementia. Early MCI (EMCI) participants had a 133 milder episodic memory impairment compared to LMCI (Wechsler Memory Scale Logical 134 Memory II scores ~0.5 and 1.5 SD below the mean of CN participants). Participants that met 135 NINCDS/ADRDA Alzheimer's Criteria and a CDR of 0.5 or 1.0 were categorised as probable AD. 136

137

### 138 2.2 CSF biomarkers, hippocampal volume, memory, and executive function

We included all participants who had the following baseline data: diagnosis in the ADNI 139 140 database, cerebrospinal fluid (CSF) levels for A $\beta$ , tau and phosphorylated tau (ptau), had a brain MRI scan, and underwent a battery of neuropsychological tests (total n = 1,460, n = 630 females, 141 n=830 males; Table 1). Data included in our analyses were: demographics (age, years of 142 143 education, and ethnicity), baseline diagnosis (cognitively normal, CN; EMCI; LMCI; or probable AD), number of APOE  $\varepsilon$ 4 alleles (0, 1 or 2), CSF A $\beta$  (pg/ml), CSF tau (pg/ml), and CSF p-tau 144 (pg/ml), hippocampal volume (mm<sup>3</sup>), ADNI executive function z-scores, and ADNI memory z-145 146 scores (using data from the ADNI neuropsychological battery and validated in Crane et al., 2012; Gibbons et al., 2012). The executive function score included WAIS-R Digit Symbol Substitution, 147 148 Digit Span Backwards, Trails A and B, Category Fluency, and Clock Drawing (Gibbons et al., 149 2012). The composite memory score included Rey Auditory Verbal Learning Test, AD

Assessment Schedule - Cognition, Mini-Mental State Examination, and Logical Memory data 150 (Crane et al., 2012). APOE genotype was determined from EDTA blood samples collected at 151 baseline (for a detailed protocol see: Shaw et al., 2009). Tau and Aβ levels were determined in 152 CSF collected in the morning after an overnight fast and using the micro-bead-based multiplex 153 immunoassay, the INNO-BIA AlzBio3 RUO test (Fujirebio, Ghent, Belgium) on the Luminex 154 155 platform (for details see: Shaw et al., 2009). MRI scans were obtained according to standardised 156 protocol (http://adni.loni.usc.edu/methods/mri-analysis/mri-acquisition/). Hippocampal volume 157 data were analysed using FreeSurfer (https://surfer.nmr.mgh.harvard.edu) version 4.3 for ADNI 158 1 and version 5.1 for ADNI GO and 2 at the University of California – San Francisco (http://adni.loni.usc.edu/methods/). Sex differences in hippocampal volume are influenced by 159 controlling factors such as intracranial volume (Lotze et al., 2019; Tan et al., 2016). In the 160 161 present study, we corrected hippocampus volume using two different methods. The first method (regression method) used the method in Mormino et al. (2014) and Jack et al. (2012) using the 162 163 residuals of the linear regression between hippocampal volume and total intracranial volume. We also compared another widely used volume correction method (Sohn et al., 2018; Sundermann et 164 al., 2018; meta-analysis by Tan et al., 2016) by dividing hippocampal volume with intracranial 165 166 volume to directly compare the different correction methods.

167

168 *2.3 Statistical Methods* 

We compared all available data for each study variable between the sexes using the
Wilcoxon rank sum test for continuous variables and Fisher's exact test for categorical variables.
We used general linear models to determine the relationships between sex, APOE genotype
(non-carriers or carriers of APOEɛ4 alleles), and diagnosis status (CN, EMCI, LMCI, and

probable AD) as predictor variables, and AD biomarkers, corrected hippocampal volume, and 173 cognitive ability, as dependent variables. All models included age and years of education as a 174 175 covariate. All models initially included the three-way interaction between sex, APOE genotype, and diagnosis; if this interaction was not significant, it was removed from the model to estimate 176 the two way interactions (sex and APOE genotype, sex and diagnosis, APOE genotype and 177 178 diagnosis). If no two-way interactions were significant, these were removed from the model to estimate the main effects of sex, APOE genotype, and diagnosis. Significance was based on the 179 180 likelihood ratio test, and all p-values were corrected for multiple testing using the Benjamini-181 Hochberg false discovery rate method with the family-wise error rate set to 0.05 (Benjamini and Hochberg, 1995). In total, seven p-values per dependent variable were included in each set of 182 models (interaction terms and main effects of sex, APOE, and diagnosis) resulting in 49 p-values 183 184 corrected (seven dependent variables; Tables 1 and 2). Significant interaction terms were 185 followed up using pairwise simple-effects tests with Benjamini-Hochberg p-value correction. We calculated Pearson's correlation coefficients between CSF levels of tau and Aβ by sex and APOE 186 genotype separately. We report significance differences (adjusted  $p \le 0.05$ ). All regression 187 analyses were carried out in R v3.5.1 (R Core Team, 2018). 188

189

#### 190 **3. Results**

#### 191 *3.1 Demographic information*

Table 1 gives a summary of the variables in the data set (N=1460). Overall, females were significantly younger and had fewer years of education than males (p's<0.0001) and hence age and education were used as covariates in all analyses. There were more white males than white females in our sample and more non-white females compared to non-white males (p<0.05). In

196	terms of APOE genotype, there were no sex differences in distribution of APOE genotype with
197	40% females and 38.8% males possessing one allele of APOEɛ4, and 11% females and 12% of
198	males possessing two alleles of APOEɛ4. The proportion of participants in each of the diagnosis
199	categories was significantly different for females and males (p<0.05). More females were
200	cognitively normal than males (26.7% compared to 20.8%, unadjusted p=0.01) but there were no
201	sex differences in baseline diagnosis of probable AD (females: 23.7% compared to males:
202	21.7%, unadjusted p=0.41). However, there were more males with a diagnosis of LMCI (39.5%
203	versus 32.5%, unadjusted p=0.007) but not EMCI (18.0% versus 17.1%, unadjusted p=0.74)
204	compared to females.
205	We tested whether sex, APOE genotype (non-carriers or carriers of APOEɛ4 alleles), and
206	diagnosis status (CN, EMCI, LMCI, and probable AD) influenced cognitive ability, corrected
207	hippocampal volume, and CSF biomarkers of AD in one model. However, we did not find
208	significant interactions between these three factors in any of the models (i.e. none of the three-
209	way interactions were significant). We did find significant two-way interactions between sex and
210	APOE genotype, sex and diagnosis, and APOE genotype and diagnosis (Table 2) on these
211	dependent variables, which are discussed in turn below.
212	

## 213 3.2. Sex and APOE genotype were associated with changes in CSF AD biomarkers

We found significant interactions between sex and APOE genotype for CSF tau, and ptau (p=0.005 and 0.006, respectively), and a trend for CSF A $\beta$  (p=0.051; Table 2). Tau and p-tau levels were significantly higher in female carriers of APOE $\epsilon$ 4 alleles compared to male carriers (all p's<0.0001; Fig. 1 A and B) but no sex differences were detected in non-carriers of APOE $\epsilon$ 4 alleles (p>0.3). Although CSF tau and p-tau levels were also higher in males with APOE $\epsilon$ 4

219	genotype, the difference in levels between carriers and non-carriers was more pronounced in
220	females (standardized regression coefficients for tau and ptau: 0.46 and 0.49 in females and 0.19
221	and 0.24 in males). For CSF A $\beta$ , post-hoc comparisons showed that female APOE $\epsilon$ 4 carriers had
222	higher levels compared to males carriers (p=0.04) but there were no sex differences in non-
223	carriers (p=0.6; Fig. 1 C). Levels of CSF A $\beta$ were lower in both sexes in carriers of APOE $\epsilon$ 4
224	alleles but the difference between carriers and non-carriers was more pronounced in males than
225	in females, irrespective of diagnosis (standardized regression coefficients for A $\beta$ : -0.58 in
226	females and -0.71 in males). There were no significant sex by diagnosis interactions for AD
227	biomarkers (Table 2).
228	We next investigated the relationship, using correlations, between CSF tau and A $\beta$ levels
229	in males and females and by APOE genotype (Table 3). We found significant negative

alleles (r=-0.262, p<0.0001; r=-0. 195, p=0.008, respectively). However, in carriers of APOE $\epsilon$ 4 alleles, a significant negative correlation was found only in females (r=-0.219, p=0.001) but not in males (r=-0.046, p=0.44).

correlations between CSF levels of tau and A $\beta$  in male and female non-carriers of APOE $\epsilon$ 4

234

230

*3.3. Sex and diagnosis were associated with changes in memory scores* 

We found a significant interaction between sex and diagnosis for ADNI memory z-scores (p=0.048; Table 2). Females had significantly higher memory z-scores than males in the CN, EMCI, and LMCI groups (p<0.001, p<0.001, p<0.01, respectively) while no sex differences were detected in probable AD (p=0.1). Thus, severity of diagnosis decreased memory scores to a greater extent in females, such that there was no longer a sex differences in memory scores in individuals with AD (Fig. 2). CSF tau and Aβ were each significantly correlated with memory zscores in both sexes, regardless of genotype (Table 3). There were no significant sex by APOEgenotype interactions for memory scores (Table 2).

244

3.4. Diagnosis and APOE are associated with changes in memory, hippocampal volume, and
tau-pathology

Two-way interactions between diagnosis and APOE genotype were detected for memory z-scores (p=0.006), hippocampal volume (the two correction methods; both p's<0.001), and CSF tau (p=0.014) and ptau levels (p=0.029) but not for executive function scores or CSF A $\beta$  levels. As expected, increasing severity of diagnosis decreases memory z-scores in carriers and noncarriers of APOE $\epsilon$ 4 alleles (p's<0.001). However, carrying APOE $\epsilon$ 4 alleles decreased memory scores in the LCMI group (p<0.0001), but not in the CN, EMCI, and probable AD groups (all p's>0.2), compared to non-carriers.

254 For both methods of hippocampal volume calculation, we found that, irrespective of sex, 255 carriers of APOE<sub>E</sub>4 alleles had a smaller volume compared to non-carriers in LMCI and probable AD individuals (regression method: p<0.0001 and p=0.0004, respectively; ratio 256 method: p=0.0001 and p=0.001, respectively). There were no significant differences in 257 258 hippocampal volume between carriers and non-carriers of APOEɛ4 alleles in the EMCI and CN 259 groups (p's>0.5). In non-carriers, severity of diagnosis was associated with a smaller 260 hippocampal volume, regardless of method of correction (AD< LMCI< EMCI< CN; p's<0.01). 261 In carriers of APOEɛ4 alleles, EMCI diagnosis did not significantly affect hippocampal volume 262 compared to CN individuals with both methods of correction (p's>0.7) while there was a 263 reduction in hippocampal volume in probable AD and LMCI (AD<LMCI<CN; p's<0.0001).

264	There were no significant sex by diagnosis or sex by APOE genotype interactions for
265	hippocampal volume (Table 2).

266	CSF tau and ptau levels increased with the severity of diagnosis but this was affected by
267	APOE genotype (p=0.014 and p=0.029, respectively). Carrying APOEɛ4 alleles resulted in
268	higher levels of CSF tau and ptau in EMCI and LMCI (all p's<0.0001), but not in CN or
269	probable AD, individuals (p's>0.17). Regardless of sex, the difference in CSF tau and ptau levels
270	between non-carriers and carriers of APOEE4 alleles was reduced in individuals with probable
271	AD compared to EMCI and LMCI diagnoses.
272	
273	3.5. Sex is associated with hippocampal volume
274	Males had a larger hippocampus volume by the regression method, but a smaller
275	proportion of the brain was devoted to hippocampus (ratio method) when compared to females
276	(main effect of sex, p=0.005 and p<0.0001, respectively; Table 2). Sex differences in
277	hippocampal volume were observed regardless of diagnosis or APOE genotype.
278	
279	3.6. Diagnosis is associated with $A\beta$ and executive function
280	Irrespective of sex and APOE genotype, increasing severity of diagnosis was associated
281	with lower CSF A $\beta$ levels in LMCI and probable AD compared to CN individuals (p<0.0001).
282	Aβ levels were similar in CN and EMCI individuals (p=0.1). Increasing severity of diagnosis
283	was associated with lower executive function z-scores (p<0.0001), irrespective of sex and APOE
284	genotype.
285	

286 4. Discussion

In the present study, we found that APOE genotype affects AD neuropathology 287 differently in males and females. CSF tau pathology was disproportionately elevated in female 288 carriers of APOEɛ4 alleles, whereas CSF Aß was disproportionately reduced in male carriers of 289 APOE<sub>24</sub> alleles. These findings suggest that APOE genotype leads to greater AD 290 291 neuropathology in both sexes that depends on the pathology biomarker, with females more likely to show higher CSF tau levels and males to present with lower CSF A<sup>β</sup> levels (suggesting a 292 293 higher A $\beta$  deposition). Females displayed higher memory scores than males in CN, EMCI, and 294 LMCI groups but not in probable AD, which may contribute to delayed diagnosis in females (Sundermann et al., 2017) and/or to the more severe decline in memory across diagnosis in 295 296 females compared to males (Buckley et al., 2018; Irvine et al., 2012; Wang et al., 2019). 297 Interestingly, depending on the correction method, females had either smaller or larger hippocampus volume compared to males, regardless of APOE genotype or diagnosis. As 298 299 expected, increasing severity of diagnosis reduced executive function and CSF A $\beta$ , irrespective of sex and APOE genotype, and APOE genotype affected memory, hippocampal volume, and 300 tau-pathology depending on diagnosis. Previous work has demonstrated sex differences in rates 301 302 of AD and symptoms of AD (reviewed in Ferretti et al., 2018; Nebel et al., 2018). Our current study suggests that AD biomarkers (CSF tau and A $\beta$ ) are expressed differently between the sexes 303 304 with APOE genotype, suggesting different AD pathology pathways between females and males 305 carriers of APOEɛ4 alleles. These data may provide clues to better understand the sex differences in AD lifetime risk and progression. 306



We found that levels of tau and p-tau were disproportionately elevated with APOE<sup>4</sup> 309 allele expression in females compared to males. Previous ADNI studies have found a significant 310 311 interaction between sex and APOE genotype on levels of CSF tau in CN (Damoiseaux et al., 2012; but see Sampedro et al., 2015; Buckley et al., 2019a; Altmann et al., 2014) and aMCI 312 participants (Altmann et al., 2014). A recent meta-analysis found a stronger association between 313 314 APOEE4 and tau levels in CN females compared to males using ADNI and other datasets (Hohman et al., 2018). Our data extends these data by adding that the interaction between sex 315 316 and APOE genotype on CSF tau and ptau is seen regardless of diagnosis (in CN, EMCI, LMCI 317 and AD individuals). A recent study using a different cohort found that CSF ptau levels were not significantly higher in female APOEE4 carriers diagnosed with probable AD but a sex difference 318 was found in earlier stages of the disease, i.e., subjective cognitive decline and MCI (Babapour 319 320 Mofrad et al., 2020). Previous studies indicate that females with at least one APOE $\varepsilon$ 4 allele are at 321 a greater risk for developing AD earlier than are males with this allele (Altmann et al., 2014; Neu 322 et al., 2017), and sex differences in tau and p-tau may be one underlying mechanism by which this occurs but further replication with additional and larger populations are needed. 323 In contrast to tau pathology, CSF A $\beta$  levels were disproportionately reduced in male 324 325 APOE $\epsilon$ 4 carriers compared to females, suggesting a greater A $\beta$  deposition in male carriers of APOE<sub>ε4</sub> alleles, regardless of diagnosis. To date, studies have not been consistent regarding sex 326 327 differences in CSF A $\beta$  levels or A $\beta$  deposition based on APOE genotype. For example, 328 somewhat consistent with our findings some studies have found that male APOEE4 carriers have 329 lower CSF A $\beta$  levels in CN individuals (but not in aMCI individuals; Altman et al., 2014), and 330 that males, regardless of APOE status, have higher A $\beta$  deposition (using PET) than females in 331 certain brain regions (i.e., cingulate cortex; Cavedo et al., 2018). However, other studies in

cognitively healthy individuals find no sex differences in A $\beta$  deposition (Jack et al., 2015) or that 332 females have higher levels of Aβ deposition (Sundermann et al., 2018), regardless of APOE 333 genotype. Differences between studies may be due to differences between CSF and PET AB 334 levels and types of analysis. Levels of CSF tau are hypothesized to increase after CSF Aß 335 declines and A $\beta$  aggregates and deposits in the brain (Blennow et al., 2015). The association 336 337 between tau and A<sup>β</sup> is also well characterized, i.e., increasing tau PET levels are associated with 338 increasing A $\beta$  PET deposition (e.g., Maass et al., 2017). Based on this, we would have expected 339 lower CSF A $\beta$  to be associated with higher CSF tau and ptau, which is precisely what we found 340 in females, regardless of APOE genotype, but only in male non-carriers of APOE alleles. Previous work is consistent with this finding, as higher levels of tau PET were more strongly 341 associated with higher A $\beta$  burden in the entorhinal cortex in females compared to males 342 (Buckley et al., 2019b). Taken together, this suggests that the weaker relationship between tau 343 344 and A $\beta$  in males is due to APOE genotype and the stronger relationship in females between tau 345 and A $\beta$  is seen regardless of APOE genotype and these sex differences may drive inconsistences between studies. However, CSF tau and A<sup>β</sup> were similarly correlated with memory scores in 346 both sexes and APOE genotype. It is possible that depending on APOE genotype, the 347 348 neurodegeneration pathway (tau or A $\beta$ ) or timeline of pathology is different between the sexes, but whichever pathway is present, it is correlated with lower memory scores. 349

350

#### 4.2 AD diagnosis decreased memory scores to a greater extent in females

As expected, we found that the presence of APOEε4 alleles and probable AD diagnosis
were associated with reduced memory and executive function scores consistent with past
literature (Buckner, 2004; Ewers et al., 2012; Petersen et al., 2000). However, memory scores in

females were more affected with diagnosis such that the female memory advantage was reduced 355 with probable AD, and this is in line with longitudinal analyses showing females decline faster 356 357 (although this may depend on APOE genotype and A $\beta$  burden; Holland et al., 2013; Buckley et al., 2018). Executive function on the other hand was similarly reduced in females and males with 358 diagnosis. Previous studies found that females have better verbal memory compared to males 359 360 across diagnoses (CN, Jack et al., 2015; aMCI and probable AD, Sundermann et al., 2018, 2016). Here, we used the ADNI memory score developed by Crane et al. (2012) to detect abnormal 361 362 memory including language, attention, and logical memory. It is possible that verbal memory 363 may be driving the sex difference favouring females in the present study, however individual cognitive scores will need to be analysed to confirm this. In contrast, Buckley et al. (2018) found 364 no sex differences using a composite cognitive score that includes memory and executive 365 function (Preclinical Alzheimer's Cognitive Composite score with semantic processing, PACC5) 366 using ADNI and two other cohorts. Altogether, we found that in females CSF tau pathology was 367 368 increased with APOE genotype and that in CN, EMCI and LMCI females (regardless of APOE genotype) memory and executive function scores were higher compared to males suggesting 369 females have a reserve against brain pathology that delays either the onset of cognitive decline or 370 371 diagnosis (Sundermann et al., 2017). Females may also use different coping strategies which 372 delay manifestation of clinical symptoms, and in turn females may be less likely to be diagnosed 373 with MCI or AD, as is the case with other conditions such as cardiovascular disease (Norris et 374 al., 2020). Another study found that demographic differences (education and socioeconomic 375 status) can affect sex differences in cognition. Males score better in verbal learning in 376 impoverished and poor health cohorts and this is also associated with better education in males. 377 In contrast, females score better when they have better education even when using education as a

covariate (Hogervorst et al., 2012). These results suggest that more detailed neuropsychological 378 analyses are important to consider, along with the use of composite or individual cognitive 379 scores, and that education is a moderating variable in the effects of sex on neuropsychological 380 measures of cognition. The use of education as a moderating variable to influence cognitive 381 382 memory scores across diagnosis and genotype will be an important factor in future studies. 383 However, once cognitive decline begins, sex differences in memory scores are reduced (current study) and females show higher rates of declines compared to males (Buckley et al., 2018; 384 385 Holland et al., 2013; Hua et al., 2010) perhaps because the underlying tau pathology is elevated 386 in females.

Females have a higher lifetime risk of AD than males and show greater cognitive decline 387 with AD than males (reviewed by Ferretti et al., 2018; Nebel et al., 2018). The disproportionate 388 389 effect in females compared to males of (1) APOEɛ4 genotype on tau-related pathology and (2) 390 AD diagnosis on memory scores supports the idea that females have a higher burden of the 391 disease, although not all studies agree (Jack et al., 2019; reviewed in Nebel et al., 2018). Intriguingly, males are more likely to be diagnosed with aMCI compared to females (Jack et al., 392 2019), whereas females progress faster from aMCI to AD (Lin et al., 2015). These findings are 393 394 similar to those in the current study as we found more males than females diagnosed with LMCI but no sex difference in frequency in probable AD. Altogether, our study and previous research 395 396 suggests that AD females "catch up" to males and sex differences in tau-related pathology found 397 in the current study may be the underlying mechanism for this accelerated transition.

398

399 *4.3 Sex differences in hippocampal volume depended on correction method* 

400 We found that the presence of APOE $\varepsilon$ 4 alleles and probable AD diagnosis were associated with reduced corrected hippocampal volume (both methods of correction) consistent 401 402 with previous literature (Buckner, 2004; Ewers et al., 2012; Jack et al., 2000; Li et al., 2016; Petersen et al., 2000). Curiously, depending on the correction method, females had larger or 403 smaller hippocampal volume compared to males. Females had smaller corrected hippocampal 404 405 volume using the residuals of the linear regression between hippocampal volume and total 406 intracranial volume (regression method) but larger ratio of hippocampal/intracranial volume 407 compared to males. Similar findings have been shown before as sex differences depend on 408 whether hippocampal volume is corrected for by intracranial volume or total brain volume, and the method of correction (Tan et al., 2016). In their meta-analysis, Tan et al. (2016) conclude 409 that sex differences in hippocampal volume are modest and highly depends on whether or not a 410 correction was applied and the method of correction which is supported by our findings. These 411 results have important implications for understanding sex differences in diseases that influence 412 413 the integrity of the hippocampus as they lead to very different conclusions regarding hippocampal plasticity. 414

415

416 4.4 Limitations

The ADNI data are not representative of the population as it is mostly composed of white and highly educated individuals. As ethnicity (Mayeda et al., 2016; Steenland et al., 2016) and education (Sharp and Gatz, 2011) can affect incidence, prevalence and age of AD onset, our conclusions may not apply to more ethnically and socially diverse populations. Although we controlled for education levels, education in itself is an important contributing factor and may impact sex differences in cognitive decline (Hogervorst et al., 2012). It is also possible that the

protective effects of education vary with race/ethnicity (Avila et al., 2021), therefore future 423 studies in more representative populations are needed. In addition, other pathologies in these 424 425 participants, such as cancer, cardiovascular disease, diabetes, or smoking status may have influenced our measures of AD pathology, cognition, and hippocampal volume (Durazzo et al., 426 427 2014; Mezencev and Chernoff, 2020; Santiago and Potashkin, 2021). In this cohort, we did not 428 detect significant interactions between sex, APOE genotype, and diagnosis for any of the 429 endpoints analysed. Future research with large cohorts is required to further test how sex, APOE 430 genotype, and diagnosis interact together as well as how other life history characteristics such as 431 parity may play a role.

432

#### 433 **6.** Conclusion

Levels of CSF tau and p-tau were disproportionately affected by APOE genotype in 434 females compared to males, however males had a higher reduction in CSF A $\beta$  levels with APOE 435 436 genotype compared to females. Our results support the idea that there are sex differences in the manifestation and pathology of AD with APOE genotype. Interestingly, although in this cohort 437 female APOEE4 carriers had elevated tau pathology, females (regardless of APOE genotype) had 438 439 higher memory scores compared to males in CN and aMCI groups. Therefore, it is possible that females may have a reserve that protects the brain from damage to delay cognitive decline or 440 441 delay diagnosis but as the disease progresses the advantage in memory is reduced and females 442 show a faster trajectory of cognitive decline.

443

## 444 Acknowledgments

Data collection and sharing for this project was funded by the Alzheimer's Disease 445 Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD 446 ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the 447 National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, 448 and through generous contributions from the following: AbbVie, Alzheimer's Association; 449 450 Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli 451 452 Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company 453 Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development 454 LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx 455 Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal 456 Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian 457 458 Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health 459 (www.fnih.org). The grantee organization is the Northern California Institute for Research and 460 461 Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro 462 463 Imaging at the University of Southern California. Funding for this study was provided by a 464 Canadian Institutes of Health Research (CHIR) grant to LAMG (PJT-148662). PDG is funded by 465 the Alzheimer's Association of the USA and Brain Canada with the financial support of Health 466 Canada through the Brain Canada Research Fund (AARF-17-529705). The views expressed

467 herein do not necessarily represent the views of the Minister of Health or the Government of

468 Canada.

- 470 **References**
- Altmann, A., Tian, L., Henderson, V.W., Greicius, M.D., 2014. Sex modifies the APOE-related risk of developing Alzheimer disease. Annals of Neurology 75, 563–573.
  https://doi.org/10.1002/ana.24135
- Alzheimer's Association, 2017. 2017 Alzheimer's disease facts and figures. Alzheimer's & Dementia 13,
   325–373. https://doi.org/10.1016/j.jalz.2017.02.001
- Ardekani, B.A., Convit, A., Bachman, A.H., 2016. Analysis of the MIRIAD Data Shows Sex Differences
  in Hippocampal Atrophy Progression. J. Alzheimers Dis. 50, 847–857.
  https://doi.org/10.3233/JAD-150780
- Asperholm, M., Högman, N., Rafi, J., Herlitz, A., 2019. What did you do yesterday? A meta-analysis of
  sex differences in episodic memory. Psychol Bull 145, 785–821.
  https://doi.org/10.1037/bul0000197
- Avila, J.F., Rentería, M.A., Jones, R.N., Vonk, J.M.J., Turney, I., Sol, K., Seblova, D., Arias, F., HillJarrett, T., Levy, S.-A., Meyer, O., Racine, A.M., Tom, S.E., Melrose, R.J., Deters, K., Medina,
  L.D., Carrión, C.I., Díaz-Santos, M., Byrd, D.R., Chesebro, A., Colon, J., Igwe, K.C., Maas, B.,
  Brickman, A.M., Schupf, N., Mayeux, R., Manly, J.J., 2021. Education differentially contributes
  to cognitive reserve across racial/ethnic groups. Alzheimer's & Dementia 17, 70–80.
  https://doi.org/10.1002/alz.12176
- Babapour Mofrad, R., Tijms, B.M., Scheltens, P., Barkhof, F., van der Flier, W.M., Sikkes, S.A.M.,
  Teunissen, C.E., 2020. Sex differences in CSF biomarkers vary by Alzheimer disease stage and
  APOE ε4 genotype. Neurology 95, e2378–e2388.
- 491 https://doi.org/10.1212/WNL.00000000010629
- Benjamini, Y., Hochberg, Y., 1995. Controlling the False Discovery Rate: A Practical and Powerful
   Approach to Multiple Testing. Journal of the Royal Statistical Society. Series B (Methodological)
   57, 289–300.
- Blennow, K., Dubois, B., Fagan, A.M., Lewczuk, P., de Leon, M.J., Hampel, H., 2015. Clinical utility of
  cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. Alzheimer's &
  Dementia 11, 58–69. https://doi.org/10.1016/j.jalz.2014.02.004
- Buckley, R.F., Mormino, E.C., Amariglio, R.E., Properzi, M.J., Rabin, J.S., Lim, Y.Y., Papp, K.V.,
  Jacobs, H.I.L., Burnham, S., Hanseeuw, B.J., Doré, V., Dobson, A., Masters, C.L., Waller, M.,
  Rowe, C.C., Maruff, P., Donohue, M.C., Rentz, D.M., Kirn, D., Hedden, T., Chhatwal, J.,
  Schultz, A.P., Johnson, K.A., Villemagne, V.L., Sperling, R.A., 2018. Sex, amyloid, and APOE
  ε4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-
- 503 characterized cohorts. Alzheimer's & Dementia 14, 1193–1203.
   504 https://doi.org/10.1016/j.jalz.2018.04.010
- Buckley, R.F., Mormino, E.C., Chhatwal, J., Schultz, A.P., Rabin, J.S., Rentz, D.M., Acar, D., Properzi,
  M.J., Dumurgier, J., Jacobs, H., Gomez-Isla, T., Johnson, K.A., Sperling, R.A., Hanseeuw, B.J.,
  2019a. Associations between baseline amyloid, sex, and APOE on subsequent tau accumulation
  in cerebrospinal fluid. Neurobiology of Aging 78, 178–185.
- 509 https://doi.org/10.1016/j.neurobiolaging.2019.02.019
- Buckley, R.F., Mormino, E.C., Rabin, J.S., Hohman, T.J., Landau, S., Hanseeuw, B.J., Jacobs, H.I.L.,
  Papp, K.V., Amariglio, R.E., Properzi, M.J., Schultz, A.P., Kirn, D., Scott, M.R., Hedden, T.,
  Farrell, M., Price, J., Chhatwal, J., Rentz, D.M., Villemagne, V.L., Johnson, K.A., Sperling, R.A.,

- 513 2019b. Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults. JAMA Neurol 514 515 76, 542-551. https://doi.org/10.1001/jamaneurol.2018.4693 Buckner, R.L., 2004. Memory and Executive Function in Aging and AD: Multiple Factors that Cause 516 Decline and Reserve Factors that Compensate. Neuron 44, 195–208. 517 https://doi.org/10.1016/j.neuron.2004.09.006 518 519 Cavedo, E., Chiesa, P.A., Houot, M., Ferretti, M.T., Grothe, M.J., Teipel, S.J., Lista, S., Habert, M.-O., 520 Potier, M.-C., Dubois, B., Hampel, H., Bakardjian, H., Benali, H., Bertin, H., Bonheur, J., 521 Boukadida, L., Boukerrou, N., Cavedo, E., Chiesa, P., Colliot, O., Dubois, B., Dubois, M., Epelbaum, S., Gagliardi, G., Genthon, R., Habert, M.-O., Hampel, H., Houot, M., Kas, A., 522 Lamari, F., Levy, M., Lista, S., Metzinger, C., Mochel, F., Nyasse, F., Poisson, C., Potier, M.-C., 523 524 Revillon, M., Santos, A., Andrade, K.S., Sole, M., Surtee, M., de Schotten, M.T., Vergallo, A., 525 Younsi, N., Aguilar, L.F., Babiloni, C., Baldacci, F., Benda, N., Black, K.L., Bokde, A.L.W., Bonuccelli, U., Broich, K., Bun, R.S., Cacciola, F., Castrillo, J., Cavedo, E., Ceravolo, R., Chiesa, 526 P.A., Colliot, O., Coman, C.-M., Corvol, J.-C., Cuello, A.C., Cummings, J.L., Depypere, H., 527 Dubois, B., Duggento, A., Durrleman, S., Escott-Price, V., Federoff, H., Ferretti, M.T., Fiandaca, 528 M., Frank, R.A., Garaci, F., Genthon, R., George, N., Giorgi, F.S., Graziani, M., Haberkamp, M., 529 530 Habert, M.-O., Hampel, H., Herholz, K., Karran, E., Kim, S.H., Koronyo, Y., Koronyo-Hamaoui, M., Lamari, F., Langevin, T., Lehéricy, S., Lista, S., Lorenceau, J., Mapstone, M., Neri, C., 531 532 Nistico, R., Nyasse-Messene, F., O'bryant, S.E., Perry, G., Ritchie, C., Rojkova, K., Rossi, S., Saidi, A., Santarnecchi, E., Schneider, L.S., Sporns, O., Toschi, N., Verdooner, S.R., Vergallo, 533 A., Villain, N., Welikovitch, L.A., Woodcock, J., Younesi, E., 2018. Sex differences in functional 534 535 and molecular neuroimaging biomarkers of Alzheimer's disease in cognitively normal older 536 adults with subjective memory complaints. Alzheimer's & Dementia 14, 1204-1215. https://doi.org/10.1016/j.jalz.2018.05.014 537 538 Crane, P.K., Carle, A., Gibbons, L.E., Insel, P., Mackin, R.S., Gross, A., Jones, R.N., Mukherjee, S., 539 Curtis, S.M., Harvey, D., Weiner, M., Mungas, D., Alzheimer's Disease Neuroimaging Initiative, 540 2012. Development and assessment of a composite score for memory in the Alzheimer's Disease 541 Neuroimaging Initiative (ADNI). Brain Imaging Behav 6, 502–516. https://doi.org/10.1007/s11682-012-9186-z 542 543 Damoiseaux, J.S., Seeley, W.W., Zhou, J., Shirer, W.R., Coppola, G., Karydas, A., Rosen, H.J., Miller, 544 B.L., Kramer, J.H., Greicius, M.D., Alzheimer's Disease Neuroimaging Initiative, 2012. Gender 545 modulates the APOE ɛ4 effect in healthy older adults: convergent evidence from functional brain connectivity and spinal fluid tau levels. J. Neurosci. 32, 8254-8262. 546 https://doi.org/10.1523/JNEUROSCI.0305-12.2012 547 548 Durazzo, T.C., Mattsson, N., Weiner, M.W., 2014. Smoking and increased Alzheimer's disease risk: A
  - Durazzo, T.C., Mattsson, N., Weiner, M.W., 2014. Smoking and increased Alzheimer's disease risk: A
     review of potential mechanisms. Alzheimers Dement 10, S122–S145.
     https://doi.org/10.1016/j.jalz.2014.04.009
  - Ewers, M., Walsh, C., Trojanowski, J.Q., Shaw, L.M., Petersen, R.C., Jack, C.R., Feldman, H.H., Bokde,
    A.L.W., Alexander, G.E., Scheltens, P., Vellas, B., Dubois, B., Weiner, M., Hampel, H., 2012.
    Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based
    upon biomarkers and neuropsychological test performance. Neurobiology of Aging 33, 12031214.e2. https://doi.org/10.1016/j.neurobiolaging.2010.10.019
  - Ferretti, M.T., Iulita, M.F., Cavedo, E., Chiesa, P.A., Schumacher Dimech, A., Santuccione Chadha, A.,
    Baracchi, F., Girouard, H., Misoch, S., Giacobini, E., Depypere, H., Hampel, H., 2018. Sex
    differences in Alzheimer disease the gateway to precision medicine. Nature Reviews
    Neurology 14, 457–469. https://doi.org/10.1038/s41582-018-0032-9
  - Gaillard, A., Fehring, D.J., Rossell, S.L., 2020. A systematic review and meta-analysis of behavioural sex
     differences in executive control. European Journal of Neuroscience.
     https://doi.org/10.1111/ejn.14946

- Gibbons, L.E., Carle, A.C., Mackin, R.S., Harvey, D., Mukherjee, S., Insel, P., Curtis, S.M., Mungas, D.,
  Crane, P.K., Alzheimer's Disease Neuroimaging Initiative, 2012. A composite score for
  executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI)
  participants with baseline mild cognitive impairment. Brain Imaging Behav 6, 517–527.
  https://doi.org/10.1007/s11682-012-9176-1
- Hogervorst, E., Rahardjo, T.B., Jolles, J., Brayne, C., Henderson, V.W., 2012. Gender differences in
   verbal learning in older participants. Aging Health 8, 493–507. https://doi.org/10.2217/ahe.12.56
- Hohman, T.J., Dumitrescu, L., Barnes, L.L., Thambisetty, M., Beecham, G., Kunkle, B., Gifford, K.A.,
  Bush, W.S., Chibnik, L.B., Mukherjee, S., Jager, P.L.D., Kukull, W., Crane, P.K., Resnick, S.M.,
  Keene, C.D., Montine, T.J., Schellenberg, G.D., Haines, J.L., Zetterberg, H., Blennow, K.,
  Larson, E.B., Johnson, S.C., Albert, M., Bennett, D.A., Schneider, J.A., Jefferson, A.L., 2018.
  Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau. JAMA
  Neurol 75, 989–998. https://doi.org/10.1001/jamaneurol.2018.0821
- Holland, D., Desikan, R.S., Dale, A.M., McEvoy, L.K., Alzheimer's Disease Neuroimaging Initiative,
  2013. Higher rates of decline for women and apolipoprotein E epsilon4 carriers. AJNR Am J
  Neuroradiol 34, 2287–2293. https://doi.org/10.3174/ajnr.A3601
- Hua, X., Hibar, D.P., Lee, S., Toga, A.W., Jack, C.R., Weiner, M.W., Thompson, P.M., 2010. Sex and
  age differences in atrophic rates: an ADNI study with n=1368 MRI scans. Neurobiology of Aging
  31, 1463–1480. https://doi.org/10.1016/j.neurobiolaging.2010.04.033
- Irvine, K., Laws, K.R., Gale, T.M., Kondel, T.K., 2012. Greater cognitive deterioration in women than
   men with Alzheimer's disease: a meta analysis. J Clin Exp Neuropsychol 34, 989–998.
   https://doi.org/10.1080/13803395.2012.712676
- Jack, C.R., Dickson, D.W., Parisi, J.E., Xu, Y.C., Cha, R.H., O'Brien, P.C., Edland, S.D., Smith, G.E.,
  Boeve, B.F., Tangalos, E.G., Kokmen, E., Petersen, R.C., 2002. Antemortem MRI Findings
  Correlate with Hippocampal Neuropathology in Typical Aging and Dementia. Neurology 58,
  750–757.
- Jack, C.R., Knopman, D.S., Weigand, S.D., Wiste, H.J., Vemuri, P., Lowe, V., Kantarci, K., Gunter, J.L.,
  Senjem, M.L., Ivnik, R.J., Roberts, R.O., Rocca, W.A., Boeve, B.F., Petersen, R.C., 2012. An
  operational approach to National Institute on Aging–Alzheimer's Association criteria for
  preclinical Alzheimer disease. Annals of Neurology 71, 765–775.
  https://doi.org/10.1002/ana.22628
- Jack, C.R., Petersen, R.C., Xu, Y., O'Brien, P.C., Smith, G.E., Ivnik, R.J., Boeve, B.F., Tangalos, E.G.,
   Kokmen, E., 2000. Rates of hippocampal atrophy correlate with change in clinical status in aging
   and AD. Neurology 55, 484–489. https://doi.org/10.1212/wnl.55.4.484
- Jack, C.R., Therneau, T.M., Weigand, S.D., Wiste, H.J., Knopman, D.S., Vemuri, P., Lowe, V.J., Mielke,
  M.M., Roberts, R.O., Machulda, M.M., Graff-Radford, J., Jones, D.T., Schwarz, C.G., Gunter,
  J.L., Senjem, M.L., Rocca, W.A., Petersen, R.C., 2019. Prevalence of Biologically vs Clinically
  Defined Alzheimer Spectrum Entities Using the National Institute on Aging–Alzheimer's
- Association Research Framework. JAMA Neurol. https://doi.org/10.1001/jamaneurol.2019.1971
  Jack, C.R., Wiste, H.J., Weigand, S.D., Knopman, D.S., Vemuri, P., Mielke, M.M., Lowe, V., Senjem,
  M.L., Gunter, J.L., Machulda, M.M., Gregg, B.E., Pankratz, V.S., Rocca, W.A., Petersen, R.C.,
- 6042015. Age, Sex, and APOE ε4 Effects on Memory, Brain Structure, and β-Amyloid Across the605Adult Life Span. JAMA Neurol 72, 511–519. https://doi.org/10.1001/jamaneurol.2014.4821
- Kidron, D., Black, S.E., Stanchev, P., Buck, B., Szalai, J.P., Parker, J., Szekely, C., Bronskill, M.J., 1997.
   Quantitative MR volumetry in Alzheimer's disease: Topographic markers and the effects of sex and education. Neurology 49, 1504–1512. https://doi.org/10.1212/WNL.49.6.1504
- Li, B., Shi, J., Gutman, B.A., Baxter, L.C., Thompson, P.M., Caselli, R.J., Wang, Y., 2016. Influence of
   APOE Genotype on Hippocampal Atrophy over Time An N=1925 Surface-Based ADNI Study.
   PLoS One 11. https://doi.org/10.1371/journal.pone.0152901
- Lin, K.A., Choudhury, K.R., Rathakrishnan, B.G., Marks, D.M., Petrella, J.R., Doraiswamy, P.M., 2015.
   Marked gender differences in progression of mild cognitive impairment over 8 years.

614 Alzheimer's & Dementia: Translational Research & Clinical Interventions 1, 103–110. https://doi.org/10.1016/j.trci.2015.07.001 615 616 Liu, M., Paranjpe, M.D., Zhou, X., Duy, P.Q., Goyal, M.S., Benzinger, T.L.S., Lu, J., Wang, R., Zhou, 617 Y., 2019. Sex modulates the ApoE ɛ4 effect on brain tau deposition measured by 18F-AV-1451 618 PET in individuals with mild cognitive impairment. Theranostics 9, 4959–4970. https://doi.org/10.7150/thno.35366 619 620 Lotze, M., Domin, M., Gerlach, F.H., Gaser, C., Lueders, E., Schmidt, C.O., Neumann, N., 2019. Novel 621 findings from 2,838 Adult Brains on Sex Differences in Gray Matter Brain Volume. Scientific 622 Reports 9, 1671. https://doi.org/10.1038/s41598-018-38239-2 Maass, A., Landau, S., Baker, S.L., Horng, A., Lockhart, S.N., La Joie, R., Rabinovici, G.D., Jagust, 623 W.J., 2017. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's 624 625 disease. NeuroImage 157, 448-463. https://doi.org/10.1016/j.neuroimage.2017.05.058 626 Mayeda, E.R., Glymour, M.M., Quesenberry, C.P., Whitmer, R.A., 2016. Inequalities in dementia incidence between six racial and ethnic groups over 14 years. Alzheimer's & Dementia 12, 216-627 224. https://doi.org/10.1016/j.jalz.2015.12.007 628 629 Mezencev, R., Chernoff, Y.O., 2020. Risk of Alzheimer's Disease in Cancer Patients: Analysis of 630 Mortality Data from the US SEER Population-Based Registries. Cancers (Basel) 12. 631 https://doi.org/10.3390/cancers12040796 Mormino, E.C., Betensky, R.A., Hedden, T., Schultz, A.P., Amariglio, R.E., Rentz, D.M., Johnson, K.A., 632 633 Sperling, R.A., 2014. Synergistic Effect of β-Amyloid and Neurodegeneration on Cognitive Decline in Clinically Normal Individuals. JAMA Neurol 71, 1379–1385. 634 https://doi.org/10.1001/jamaneurol.2014.2031 635 636 Nebel, R.A., Aggarwal, N.T., Barnes, L.L., Gallagher, A., Goldstein, J.M., Kantarci, K., Mallampalli, M.P., Mormino, E.C., Scott, L., Yu, W.H., Maki, P.M., Mielke, M.M., 2018. Understanding the 637 638 impact of sex and gender in Alzheimer's disease: A call to action. Alzheimer's & Dementia 14, 639 1171-1183. https://doi.org/10.1016/j.jalz.2018.04.008 640 Neu, S.C., Pa, J., Kukull, W., Beekly, D., Kuzma, A., Gangadharan, P., Wang, L.-S., Romero, K., 641 Arneric, S.P., Redolfi, A., Orlandi, D., Frisoni, G.B., Au, R., Devine, S., Auerbach, S., Espinosa, A., Boada, M., Ruiz, A., Johnson, S.C., Koscik, R., Wang, J.-J., Hsu, W.-C., Chen, Y.-L., Toga, 642 643 A.W., 2017. Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-644 analysis. JAMA Neurol. https://doi.org/10.1001/jamaneurol.2017.2188 Norris, C.M., Yip, C.Y.Y., Nerenberg, K.A., Clavel, M.-A., Pacheco, C., Foulds, H.J.A., Hardy, M., 645 646 Gonsalves, C.A., Jaffer, S., Parry, M., Colella, T.J.F., Dhukai, A., Grewal, J., Price, J.A.D., Levinsson, A.L.E., Hart, D., Harvey, P.J., Van Spall, H.G.C., Sarfi, H., Sedlak, T.L., Ahmed, 647 S.B., Baer, C., Coutinho, T., Edwards, J.D., Green, C.R., Kirkham, A.A., Srivaratharajah, K., 648 649 Dumanski, S., Keeping-Burke, L., Lappa, N., Reid, R.D., Robert, H., Smith, G., Martin-Rhee, M., Mulvagh, S.L., 2020. State of the Science in Women's Cardiovascular Disease: A Canadian 650 Perspective on the Influence of Sex and Gender. J Am Heart Assoc 9, e015634. 651 652 https://doi.org/10.1161/JAHA.119.015634 Petersen, R.C., Aisen, P.S., Beckett, L.A., Donohue, M.C., Gamst, A.C., Harvey, D.J., Jack, C.R., Jagust, 653 654 W.J., Shaw, L.M., Toga, A.W., Trojanowski, J.Q., Weiner, M.W., 2010. Alzheimer's Disease 655 Neuroimaging Initiative (ADNI). Neurology 74, 201–209. https://doi.org/10.1212/WNL.0b013e3181cb3e25 656 657 Petersen, R.C., Jack, C.R., Xu, Y.C., Waring, S.C., O'Brien, P.C., Smith, G.E., Ivnik, R.J., Tangalos, E.G., Boeve, B.F., Kokmen, E., 2000. Memory and MRI-based hippocampal volumes in aging 658 and AD. Neurology 54, 581-587. https://doi.org/10.1212/wnl.54.3.581 659 660 R Core Team, 2018. A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/. 661 Riedel, B.C., Thompson, P.M., Brinton, R.D., 2016. Age, APOE and sex: Triad of risk of Alzheimer's 662 disease. The Journal of Steroid Biochemistry and Molecular Biology 160, 134–147. 663 https://doi.org/10.1016/j.jsbmb.2016.03.012 664

- 665 Sampedro, F., Vilaplana, E., de Leon, M.J., Alcolea, D., Pegueroles, J., Montal, V., Carmona-Iragui, M., Sala, I., Sánchez-Saudinos, M.-B., Antón-Aguirre, S., Morenas-Rodríguez, E., Camacho, V., 666 Falcón, C., Pavía, J., Ros, D., Clarimón, J., Blesa, R., Lleó, A., Fortea, J., Alzheimer's Disease 667 668 Neuroimaging Initiative, 2015. APOE-by-sex interactions on brain structure and metabolism in healthy elderly controls. Oncotarget 6, 26663–26674. https://doi.org/10.18632/oncotarget.5185 669
- Santiago, J.A., Potashkin, J.A., 2021. The Impact of Disease Comorbidities in Alzheimer's Disease. 670 671 Front. Aging Neurosci. 13. https://doi.org/10.3389/fnagi.2021.631770
- 672 Sharp, E.S., Gatz, M., 2011. The Relationship between Education and Dementia An Updated Systematic 673 Review. Alzheimer Dis Assoc Disord 25, 289–304. 674
  - https://doi.org/10.1097/WAD.0b013e318211c83c
- Shaw, L.M., Vanderstichele, H., Knapik-Czajka, M., Clark, C.M., Aisen, P.S., Petersen, R.C., Blennow, 675 676 K., Soares, H., Simon, A., Lewczuk, P., Dean, R., Siemers, E., Potter, W., Lee, V.M.-Y., 677 Trojanowski, J.Q., 2009. Cerebrospinal Fluid Biomarker Signature in Alzheimer's Disease 678 Neuroimaging Initiative Subjects. Ann Neurol 65, 403-413. https://doi.org/10.1002/ana.21610
- Sohn, D., Shpanskava, K., Lucas, J.E., Petrella, J.R., Savkin, A.J., Tanzi, R.E., Samatova, N.F., 679 680 Doraiswamy, P.M., 2018. Sex Differences in Cognitive Decline in Subjects with High Likelihood 681 of Mild Cognitive Impairment due to Alzheimer's disease. Scientific Reports 8, 7490. 682 https://doi.org/10.1038/s41598-018-25377-w
- Steenland, K., Goldstein, F.C., Levey, A., Wharton, W., 2016. A Meta-Analysis of Alzheimer's Disease 683 684 Incidence and Prevalence Comparing African-Americans and Caucasians. J. Alzheimers Dis. 50, 685 71-76. https://doi.org/10.3233/JAD-150778
- 686 Sundermann, E.E., Biegon, A., Rubin, L.H., Lipton, R.B., Landau, S., Maki, P.M., Alzheimer's Disease 687 Neuroimaging Initiative, 2017. Does the Female Advantage in Verbal Memory Contribute to Underestimating Alzheimer's Disease Pathology in Women versus Men? J. Alzheimers Dis. 56, 688 689 947-957. https://doi.org/10.3233/JAD-160716
- 690 Sundermann, E.E., Biegon, A., Rubin, L.H., Lipton, R.B., Mowrey, W., Landau, S., Maki, P.M., 2016. 691 Better verbal memory in women than men in MCI despite similar levels of hippocampal atrophy. 692 Neurology 86, 1368–1376. https://doi.org/10.1212/WNL.00000000002570
- Sundermann, E.E., Tran, M., Maki, P.M., Bondi, M.W., 2018. Sex differences in the association between 693 694 apolipoprotein E £4 allele and Alzheimer's disease markers. Alzheimer's & Dementia: Diagnosis, 695 Assessment & Disease Monitoring 10, 438–447. https://doi.org/10.1016/j.dadm.2018.06.004
- Tan, A., Ma, W., Vira, A., Marwha, D., Eliot, L., 2016. The human hippocampus is not sexually-696 697 dimorphic: Meta-analysis of structural MRI volumes. NeuroImage 124, 350-366. 698 https://doi.org/10.1016/j.neuroimage.2015.08.050
- Wang, X., Zhou, W., Ye, T., Lin, X., Zhang, J., Initiative, for A.D.N., 2019. Sex Difference in the 699 700 Association of APOE4 with Memory Decline in Mild Cognitive Impairment. Journal of 701 Alzheimer's Disease 69, 1161-1169. https://doi.org/10.3233/JAD-181234
- 702 Yagi, S., Galea, L.A.M., 2019. Sex differences in hippocampal cognition and neurogenesis.
- 703 Neuropsychopharmacology 44, 200-213. https://doi.org/10.1038/s41386-018-0208-4
- 704

705	Figure captions
706	Figure 1. A. Levels of CSF AD biomarkers tau (pg/ml; A), p-tau (pg/ml; B), and amyloid beta
707	(pg/ml; C) in ADNI participants by sex and APOE genotype (absence or presence of APOEɛ4
708	alleles).
709	
710	Figure 2. Memory scores in ADNI participants by sex and diagnosis (CN, EMCI, LMCI, AD).
711	CN, cognitively normal; EMCI, early mild cognitive impairment; LMCI, late mild cognitive
712	impairment; AD, Alzheimer's disease.
713	

## Figure 1



# Figure 2



**Table 1.** Demographic and clinical information for all participants and subdivided by sex. We collapsed APOE genotype into two groups: (1) participants with no  $\varepsilon4$  risk alleles (-/-) and (2) participants carrying any  $\varepsilon4$  alleles (homozygous  $\varepsilon4/\varepsilon4$  and heterozygous  $\varepsilon4/-$ ). Biomarkers for AD are from cerebrospinal fluid. Volume of the hippocampus was corrected using a regression method or using a ratio with intracranial volume (see methods). CN, cognitively normal; EMCI, early mild cognitive impairment; LMCI, late mild cognitive impairment; AD, Alzheimer's disease.

				Sex		
		Total No. 1.460	Female	Male	P-value	
Age		110. 1,400	N0. 030	NO. 030		
Age Maan (SD)		74 12 (+7 25)	72 15 (+7 28)	74 97 (+7 14)	< 0.0001	
Education (voors)	)	74.13 (±7.23)	73.13 (±7.28)	74.87 (±7.14)	< 0.0001	
Moon (SD)	)	15 92 (+2 99)	$15 15 (\pm 2.70)$	16 24 (+2 95)	< 0.0001	
Fthnicity		15.65 (±2.66)	15.15 (±2.79)	10.34 (±2.83)	< 0.0001	
White		1 252 (02 600/)	572 (00 05%)	770 (02 860()	0.042	
Willie Not white		1,552 (92.00%)	575 (90.95%)	779 (95.80%) 51 (6.140()	0.043	
Not white Resoling diagnosi		108 (7.40%)	37 (9.05%)	51 (0.14%)		
CN	15	241 (22 404)	168 (26 70%)	172 (20.8%)	0.012	
EMCL		341(23.4%)	108(20.7%) 108(17.1%)	1/3(20.8%)	0.015	
EMCI		237 (17.6%) 522 (26.5%)	108(17.1%) 205(22.5%)	149 (18.0%)		
		220 (22 5%)	203 (32.3%)	528 (59.5%) 180 (21.7%)		
AD	mhou	329 (22.5%)	149 (23.7%)	180 (21.7%)		
APOEE4 allele nu	imber	702 (49,099()	200 (47 (20))	402 (48, 429()	0.97	
0		702 (48.08%)	300 (47.62%)	402 (48.43%)	0.87	
1 or 2		/44 (50.96%)	322 (51.11%)	422 (50.84%)		
Missing		14 (0.96%)	8 (1.27%)	6 (0.72%)		
Diagnosis by APG	OE genotype					
CN	0	236 (69.21%)	111 (66.07%)	125 (72.25%)	0.34	
	1 or 2	103 (30.21%)	55 (32.74%)	48 (27.75%)		
-	Missing	2 (0.59%)	2 (1.19%)	0		
EMCI	0	128 (49.81%)	59 (54.63%)	69 (46.31%)	0.2	
	1 or 2	123 (47.86%)	46 (42.59%)	77 (51.68%)		
	Missing	6 (2.33%)	3 (2.78%)	3 (2.01%)		
LMCI	0	233 (43.71%)	80 (39.02%)	153 (46.65%)	0.11	
	1 or 2	298 (55.91%)	124 (60.49%)	174 (53.05%)		
	Missing	2 (0.38%)	1 (0.49%)	1 (0.30%)		
AD	0	105 (31.92%)	50 (33.56%)	55 (30.56%)	0.63	
	1 or 2	220 (66.87%)	97 (65.10%)	123 (68.33%)		
	Missing	4 (1.22%)	2 (1.34%)	2 (1.11%)		
Amyloid Beta						
Mean (SD)		830.97 (±358.04)	856.41 (±346.87)	812.44 (±365.16)	0.016	
Missing		513 (35.14%)	231 (36.67%)	282 (33.98%)		
Tau						
Mean (SD)		294.38 (±137.27)	314.56 (±152.70)	279.70 (±122.91)	0.002	
Missing		513 (35.14%)	231 (36.67%)	282 (33.98%)		
PTau						
Mean (SD)		28.89 (±15.31)	30.87 (±16.95)	27.44 (±13.83)	0.007	
Missing		513 (35.14%)	231 (36.67%)	282 (33.98%)		
Volume of hippoo	campus (uncorrected,	mm <sup>3</sup> )				
Mean (SD)		6659.47 (±1176.42)	6446.71 (±1169.97)	6822.86 (±1155.87)	< 0.0001	
Missing		226 (15.48%)	94 (14.92%)	132 (15.90%)		
Volume of hippod	campus (regression co	orrected)				
Mean (SD)		6662.60 (±1137.98)	6647.21 (±1134.41)	6674.43 (±1141.38)	0.83	
Missing		226 (15.48%)	94 (14.92%)	132 (15.90%)		
Volume of hippod	campus/intracranial v	olume				
Mean (SD)		0.00436 (±0.00080)	0.00454 (±0.00082)	0.00423 (±0.00076)	< 0.0001	
Missing		226 (15.48%)	94 (14.92%)	132 (15.90%)		
Executive Function	on (ADNI_EF)					
Mean (SD)		0.02 (±0.96)	0.06 (±0.97)	-0.00 (±0.95)	0.20	
Missing	:	311 (21.30%)	145 (23.02%)	166 (20.00%)		
Memory (ADNI_	MEM)					
Mean (SD)		0.10 (±0.87)	0.21 (±0.94)	0.02 (±0.80)	0.0006	
Missing		310 (21.23%)	145 (23.02%)	165 (19.88%)		

P-values are from Wilcoxon rank sum tests for continuous variables and Fisher's exact tests for categorical variables. Missing refers to number of individuals and the percent of the total cohort that had missing data for that variable

	CSF tau		CSF pta	u	CSF amyloid b	oeta	ADNI Memory	z-scores	Hippocampus volume (n method)	regression	Hippocampus volu (ratio method)	ime	ADNI executive f	function z-
Predictors	Estimates (CI)	adjusted p	Estimates (CI)	adjusted p	Estimates (CI)	adjusted p	Estimates (CI)	adjusted p	Estimates (CI)	adjusted P	Estimates (CI)	adjusted P	Estimates (CI)	adjusted p
(Intercept)	122.07 (21.39 – 222.75) 1.88		12.35 (1.07 – 23.63) 0.17		1345.53 (1090.27 - 1600.80) -3 44		1.23 (0.83 - 1.64) -0.009		11678.92 (11048.18 - 12309.67) -56.77		0.0078 (0.0074 - 0.0083) -0.000035		1.16 (0.62 – 1.71) -0.02	
Age (years)	(0.79 – 2.97) -2.62	0.05	(0.05 - 0.29) -0.31		(-6.21 – -0.67) -0.19		(-0.00) (-0.010.01) 0.04	0.0002	(-63.75 – -49.78) -5.20	<0.0001	(-0.000035 (-0.000040.00003) -0.000012	<0.0001	(-0.020.01) 0.06	<0.0001
Education (years)	(-5.54 – 0.30) -12.49	0.04	(-0.64 - 0.02) -0.90	0.03	(-7.61 – 7.22) 14.22		(0.03 – 0.05) -0.31	<0.0001	(-22.72 – 12.33) 160.82		(-0.00003 - 0.0000001) -0.00021		(0.05 – 0.08) -0.12	<0.0001
Sex (ref = Female)	(-36.01 – 11.04)		(-3.53 – 1.74)		(-45.22 - 73.65)		(-0.440.18)		(59.29 – 262.36)	0.005	(-0.000280.00014)	<0.0001	(-0.210.03)	0.013
APOE genotype $1/2 \epsilon 4$ alleles (ref = 0 alleles)	68.10 (27.54 – 108.67)		7.89 (3.35 – 12.4)		-181.29 (-244.76 – -117.82)		0.003 (-0.13 – 0.14)		-168.09 (-383.49 – 47.30)		-0.000098 (-0.00025 - 0.00006)		-0.02 (-0.11 – 0.07)	
Diagnosis (ref = CN)						<0.0001								<0.0001
EMCI	7.3 (-23.08 – 37.68) 57.53		1.10 (-2.31 – 4.50) 6.58		-47.41 (-107.88 – 13.06) -199.57		-0.37 (-0.550.19) -0.99		-418.90 (-613.3224.5) -870.94		-0.00027 (-0.000410.00013) -0.00062		-0.36 (-0.510.22) -0.74	
LMCI	(28.00 - 87.06) 138.89		(3.27 – 9.89) 15.07		(-256.43142.71) -302.02		(-1.130.84) -1.87		(-1042.39699.49) -1335.15		(-0.000740.0005) -0.00089		(-0.850.63) -1.54	
AD	(103.05 – 174.73)		(11.05 – 19.08)		(-364.13239.92)		(-2.041.70)		(-1557.411112.89)		(-0.00100.0007)		(-1.67 – -1.41)	
Sex and APOE genotype interaction		0.005		0.006		0.051								
Male:1/2 alleles	-48.76 (-80.5916.93)		-5.30 (-8.861.73)		-81.14 (-161.74 – -0.54)									
Sex and Diagnosis interaction								0.048						
Male:EMCI							-0.04 (-0.25 – 0.17)							
Male:LMCI Male:AD							$\begin{array}{c} 0.15 \\ (-0.01 - 0.32) \\ 0.20 \\ (0.01 - 0.38) \end{array}$							
APOE genotype and							(0.01 - 0.38)							
Diagnosis interaction 1/2 alleles:EMCI	47.66	0.014	4 57	0.029			-0.15	0.006	271.86	0.0007	0.00023	0.0006		
1/2 alleles:LMCI	(-1.44 - 96.76) 39.03		(-0.94 - 10.07) 4.20				(-0.36 - 0.06) -0.28		(-38.41 - 582.13) -282.50		(0.00009 - 0.0005) -0.00017 (0.00026 - 0.00002)			
1/2 alleles:AD	-21.57 (-72.73 - 29.58)		(-1.00 - 9.39) -2.32 (-8.05 - 3.41)				(-0.430.11) -0.03 (-0.23 - 0.17)		-303.52 (-615.96 - 8.92)		-0.00030 - 0.00003) -0.00021 (-0.0004 - 0.000009)			
Observations	947		947		947	,	1145		1224		1224		1144	1
R <sup>2</sup> / R <sup>2</sup> adjusted	0.227 / 0.218		0.220 / 0.211		0.264 / 0.258	;	0.621 / 0.616		0.431 / 0.427		0.415 / 0.410		0.411 / 0.408	3

Table 2. Linear regression results for models with sex, baseline diagnosis (CN, cognitively normal; EMCI, early mild cognitive impairment; LMCI, late mild cognitive impairment; AD, Alzheimer's disease), and APOE4 genotype (non-carriers or carriers of APOE4 alleles). P-values are for overall tests and are FDR-adjusted. The three-way interactions were not significant for any of the endpoints.

**Table 3.** Correlations between CSF levels of tau and amyloid beta, CSF tau and memory scores, and CSF amyloid beta and memory scores, depending bysex and APOE genotype (non carriers versus carriers of  $\epsilon$ 4 alleles)

Variables	APOE genotype	Correlation in females	p-value	Correlation in males	p-value	
CSF tau and Aβ						
	Non carriers	-0.195 (-0.330 to - 0.053)	0.008	-0.262 (-0.372 to -0.145)	< 0.0001	
	Carriers of APOEE4 alleles	-0.219 (-0.343 to -0.088)	0.001	-0.046 (-0.160 to 0.070)	0.44	
CSF tau and memory z-scores						
	Non carriers	-0.397 (-0.532 to -0.244)	< 0.0001	-0.394 (-0.507 to -0.268)	< 0.0001	
	Carriers of APOEE4 alleles	-0.242 (-0.387 to -0.086)	0.003	-0.232 (-0.355 to -0.100)	0.0007	
CSF Aβ and memory z-scores						
	Non carriers	0.425 (0.275 to 0.555)	< 0.0001	0.305 (0.172 to 0.428)	< 0.0001	
	Carriers of APOEE4 alleles	0.407 (0.265 to 0.533)	< 0.0001	0.413 (0.295 to 0.519)	< 0.0001	